Pharmacokinetics of cephalosporins in the neonate: A review

Clinics

Volumn 66, Issue 7, 2011, Pages 1267-1274

  Pacifici, Gian Maria ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cephalosporins; Neonate; Pharmacokinetics

Indexed keywords

EID: 80052141709     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000700024     Document Type: Review

References (43)

1. Neu HC. In vitro activity of ceftazidime, a b-lactamase stable cephalosporin. J Antimicrob Chemother. 1981;8(Suppl B):131-4.
2. Williams JD. Classification of cephalosporins. Drugs. 1987;34(Suppl.2):15-22, doi: 10.2165/00003495-198700342-00004
3. Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am. 1995;79:705-19.
4. Petri WA Jr. Penicillins, cephalosporins, and other b-lactam antibiotics. In ''The pharmacological basis of therapeutics''. Brunton LL, Lazo JS, Parker KL editors. 11th edition, 2006 pp 1127-1154. New York USA
5. Martin E, Fanconi S, Kälin P, Zwingelstein C, Crevoisier C, Ruch W, et al. Ceftriaxone-bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr. 1993;152:530-4, doi: 10.1007/BF01955067
6. Gulian JM, Gonard V, Dalmasso C, Palix C. Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of 'free' bilirubin and erythrocyte-bound bilirubin. J Antimicrob. Chemother. 1987;19:823-9, doi: 10.1093/jac/19.6.823
7. Steadman E, Raisch DW, Bennett CL, Esterly JS, Becker T, Postelnick M, et al. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob. Agents. Chemother. 2010;54:1534-40, doi: 10. 1128/AAC.01111-09.
8. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991;100:1665-70.
9. Young TE, Mangum B. Antimicrobials pp 1-99. Neofax: A Manual of Drugs used in neonatal care. Edition 23rd. Thomson Reuters, Montvale 07645, New Jersey, USA 2010
10. Deguchi Y, Koshida R, Nakashima E, Watanabe R, Taniguchi N, Ichimura F, et al. Interindividual changes in volume of distribution of cefazolin in ewborn infants and its prediction based on physiological pharmacokinetic concepts. J Pharm Sci. 1988;77:674-8, doi: 10.1002/jps. 2600770807
11. Regazzi MB, Chirico G, Cristiani D, Rondini G, Rondanelli R. Cefoxitin in newborns. A clinical and pharmacokinetics study. Eur J Clin Pharmacol. 1983; 25:507-9.
12. Relund M, Pettay O. Pharmacokinetics and clinical efficacy of cefuroxime in the newborn period. Proc roy Soc Med. 1977;70:179-82.
13. Kafetzis DA, Brater DC, Kapiki AN, Papas CV, Dellagrammatics H, Papadotos CJ. Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics. J Pediatr. 1982;100:483-9.
14. McCracken GH, Threlkeld NA, Thomas ML. Pharmacokinetics of cefotaxime in newborn infants. Antimicrob Agents Chemother. 1982;21:683-4.
15. Gouyon JB, Pechinot A, Safran C, Chretien P, Sandre D, Kazmierczak A. Pharmacokinetics of cefotaxime in preterm infants. Dev Pharmacol Ther. 1990;14:29-34.
16. Crooks J, White LO, Burville LJ, Speidel BD, Reeves DS. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates. J Antimicrob Chemother. 1984;14 (Suppl. B):97-101.
17. Aujard Y, Brion F, Jacqz-Aigrain E, Kasse MC, Chretien P, Criqui C, et al. Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn. Diagn Microbiol Infect Dis. 1989;12:87-91, doi: 10.1016/0732-8893(89) 90051-5.
18. Kearns GL, Jacobs RF, Thomas BR, Darville TL, Trang JM. Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates. J Pediatrics. 1989;114:461-7, doi: 10.1016/S0022-3476(89)80573-6
19. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2010;54:1734-41, doi: 10.1128/AAC.01696-09.
20. Boccazzi A, Rizzo M, Caccamo ML, Assale BM. Comparison of the concentrations of ceftazidime in the serum of newborns infants after intravenous and intramuscular administration. Antimicrob Agents Chemother. 1983;24:955-6.
21. McCracken GH Jr, Threlkeld N, Thomas ML. Pharmacokinetics of ceftazidime in newborn infants. Antimicrob Agents Chemother. 1984;26:583-4.
22. Blumer JI, Aronoff SC, Myers CM, O'Brien CA, Klinger JD, Reed MD. Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis. Dev Pharmacol Ther. 1985;8:219-31.
23. van den Anker JN, Schoemaker RC, Hop WC, van der Heijden BJ, Weber A, Sauer PJ, et al. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther. 1995;58:650-9, doi: 10.1016/0009-9236(95)90021-7.
24. van den Anker JN, Hop WC, Schoemaker RC, van der Heijden BJ, Neijens HJ, de Groot R. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. Br J Clin Pharmacol. 1995;40:439-43.
25. van den Anker JN, Schoemaker RC, van der Heijden BJ, Broerse HM, Neijens HJ, de Groot R. Once-daily versus twice-daily administration of ceftazidime in the preterm infant. Antimicrob Agents Chemother. 1995; 39:2048-50.
26. Gentry LO. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime. Pharmacotherapy. 1985;5:254-67
27. Neu HC. Pathophysiologic basis for the use of third-generation cephalosporins. Am J Med. 1990;88(Suppl. 4A):3S-11S, doi: 10.1016/ 0002-9343(90)90321-4
28. Bint AJ, Yeoman P, Kilburn P, Anderson E, Stansfield E. The in vitro activity of ceftazidime compared with that of the other cephalosporins. J Antimicrob Chemother. 1981;8(Supple B):47-51.
29. Steele RW, Eyre LB, Bradsher RW, Weinfeld RE, Patel IH, Spicehandler J. Pharmacokinetics of ceftriaxone in pediatric patients with meningitis. Antimicrob Agents Chemother. 1983;23:191-4.
30. Mulhall A, de Louvois J, James J. Pharmacokinetics and safety of ceftriaxone in the neonate. Eur J Pediatr. 1985;144:379-82, doi: 10.1007/ BF00441782
31. McCracken GH Jr, Siegel JD, Threlkeld N, Thomas M. Ceftriaxone pharmacokinetics in newborn infants. Antimicrob Agents Chemother, 1983;23:341-3.
32. Bosso JA, Chan GM, Matsen JM. Cefoperazone pharmacokinetics in preterm infants. Antimicrob Agents Chemother. 1983;23:413-5.
33. Philips JB 3rd, Braune K, Ravis W, Cassady G, Dillon H. Pharmacokinetics of cefoperazone in newborn infants. Pediatr Pharmacol. 1984;4:193-7.
34. Rosenfeld WN, Evans HE, Batheja R, Jhaveri RC, Vohra K, Khan AJ. Pharmacokinetics of cefoperazone in full-term and premature neonates. Antimicrob Agents Chemother. 1983;23:866-9.
35. Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS. Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy. Drugs. 1981;22:423-60, doi: 10. 2165/00003495-198122060-00002.
36. Reed MD, Gooch WM 3rd, Minton SD, Tanaka-Kido J, Santos JI, Yamashita TS, et al. Ceftizoxime disposition in neonates and infants during the first six months of life. DICP. 1991;25:344-7.
37. Cutler RE, Blair AD, Burgess ED, Parks D. Pharmacokinetics of ceftizoxime. J Antimicrob Chemother. 1982;10 (Suppl C):91-7.
38. Capparelli E, Hochwald C, Rasmussen M, Parham A, Bradley J, Moya F. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother. 2005;49:2760-6, doi: 10.1128/AAC.49.7.2760-2766. 2005
39. Reed MD, Yamashita TS, Knupp CK, Veazey JM Jr, Blumer JL. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. Antimicrob Agents Chemother. 1997;41:1783-7.
40. Lima-Rogel V, Medina-Rojas EL, Del Carmen Milán-Segovia R, Noyola DE, Nieto-Aguirre K, et al. Population pharmacokinetics of cefepime in neonates with severe nosocomial infection. J Clin Pharmacol Ther. 2008;33:295-306, doi: 10.1111/j.1365-2710.2008.00913.x
41. Paap CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin. Pharmacokinet. 1990;19:280-318, doi: 10.2165/ 00003088-199019040-00003.
42. de Hoog, Mounton JW, can den Anker JN. Vancomycin. Pharmacokinetics and administration regimen in neonates. Clin Pharmacokinet. 2004;43:417-40, doi: 10.2165/00003088-200443070-00001.
43. Ellis JM, Rivera L, Reyes G, Castillo F, Marte P, Tejada M, et al. Cefepime cerebrospinal fluid concentrations in neonatal bacterial meningitis. Ann Pharmacother. 2007;41:900-1, doi: 10.1345/aph.1H585.